Maze Therapeutics (MAZE) CEO Jason Coloma Sells $104K of Stock
Jason Coloma, CEO of MAZE, sold 3,993 shares in a planned transaction on June 22, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jason Coloma, Chief Executive Officer at Maze Therapeutics, Inc. ($MAZE), sold 3,993 shares at an average price of $26, worth about $103,818, on June 22, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $MAZE is up 13.4% after 1 week, up 11.4% after 1 month and up 7.7% to date (from the $25.57 close on Jun 22, 2026).
MAZE
Maze Therapeutics, Inc.
Key Points
- Jason Coloma, CEO of MAZE, sold 3,993 shares valued at $103,818 on June 22, 2026, as part of a planned transaction.
- MAZE shares traded near $26.67 on Thursday, with analysts maintaining a 'buy' rating and setting price targets up to $110.
- Institutional peers like Deep Track Capital reduced holdings by 768,878 shares, while Paradigm Biocapital Advisors opened a new position.
Get $MAZE trade alerts by text
We text you when insiders, Congress or big funds trade $MAZE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Maze Therapeutics, Inc. alert may contain errors. Disclosures
Jason Coloma, the Chief Executive Officer of MAZE, sold 3,993 shares of the company in a planned transaction on June 22, 2026. The shares were sold at an average price of $26.00, totaling $103,818. This transaction was part of a Rule 10b5-1 trading plan, which allows company insiders to sell a predetermined number of shares at a set time.
Insider Buying and Selling at Maze Therapeutics, Inc.
On June 23, 2026, Jason Coloma also sold an additional 23,865 shares at $26.05 each, further executing his planned sales. Other insiders, including Charles Homcy, Daniel Spiegelman, Jonathan Lim, and Nancy Andrews, each acquired 18,000 shares on June 8, 2026, as unplanned purchases.
Other Institutional Activity in MAZE
Frazier Life Sciences Management, L.P. held steady with 4,567,274 shares valued at approximately $136.3 million. TRV GP IV, LLC also maintained its position with 4,473,958 shares worth about $133.5 million. Meanwhile, Deep Track Capital, LP reduced its holdings by 768,878 shares, now holding 3,477,562 shares valued at $103.8 million, an 18.1% decrease. Janus Henderson Group PLC cut its stake by 283,711 shares, leaving it with 2,858,876 shares worth $85.3 million, a 9% reduction. Paradigm Biocapital Advisors LP opened a new position with 2,744,399 shares valued at $81.9 million.
Analysts Set New Price Targets
Analysts have been active in setting price targets for MAZE, with Truist Securities maintaining a 'buy' rating and a price target of $64 on April 14, 2026. JP Morgan also maintained a 'buy' rating with a target of $58 on March 31, 2026. HC Wainwright & Co. set a higher target of $110 on March 25, 2026, maintaining their 'buy' stance. The consensus among analysts remains positive, with a 'buy' recommendation and an average price target reflecting strong growth potential.
Bottom Line
Jason Coloma's planned sale of shares reflects a strategic move under a trading plan, and it does not necessarily indicate a lack of confidence in MAZE. The company's stock continues to be viewed positively by analysts, with multiple 'buy' ratings and ambitious price targets. As always with insider transactions, it's important to consider the broader context and other factors influencing the company's performance.
Related Filing Alerts
Source: Jason Coloma's Form 4 filing on $MAZE (Jun 22, 2026). Find the original filing: MAZE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts